Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

- PMLiVE

NICE changes stance on AZ’s Lynparza after concessions

NHS patients in England and Wales to get ovarian cancer drug

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

National Institute for Health and Care Excellence NICE logo

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod

Novartis building

Novartis’ Entresto gets EU green light

Winsapproval for symptomatic chronic heart failure with reduced ejection fraction

National Institute for Health and Care Excellence NICE logo

BioMarin’s real world data sways NICE on orphan drug Vimizim

Rare genetic disorder treatment recommended in final draft guidance

Novartis building

Novartis’ Cosentyx cleared for wider use in Europe

Approved for psoriatic arthritis and ankylosing spondylitis

- PMLiVE

Cancer Drugs Fund overhaul promises faster access to drugs

Proposals suggest turning CDF into 'managed access' fund

- PMLiVE

FDA accepts Sandoz filing for biosimilar Neulasta

Theversion of Amgen's blockbuster will have a 10-month review period

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links